Nolan Jenevein, MD
Neurology · Dallas, TXNPI 1346217163
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,844 of the $17,972 with a category attached, or 60.3%. 36 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 41.7% of the total. Reporting peaked in 2021 at $7,743 and has fallen 97.8% since, to $170 in 2023.
Across 457 payments — averaging $39.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$7K
- SK Life Science, Inc.$6K
- AbbVie$715
- Neuropace, Inc.$654
- Genentech USA, Inc.$357
- Supernus Pharmaceuticals, Inc.$321
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$10,84460%
- Food & beverage$7,12940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 190 | $7,489 |
| SK Life Science, Inc. | 19 | $6,275 |
| AbbVie(2 entities) | 52 | $715 |
| Neuropace, Inc. | 15 | $654 |
| Genentech USA, Inc. | 24 | $357 |
| Supernus Pharmaceuticals, Inc. | 26 | $321 |
| UCB, Inc. | 18 | $269 |
| Novartis | 15 | $237 |
| Eisai Inc. | 21 | $193 |
| Sanofi | 10 | $186 |
| Acorda Therapeutics, Inc | 8 | $181 |
| Livanova USA, Inc. | 4 | $156 |
| Acadia Pharmaceuticals Inc | 6 | $126 |
| Amgen(2 entities) | 4 | $120 |
| EMD Serono, Inc. | 12 | $118 |
| Upsher-smith Laboratories LLC | 3 | $59 |
| Pfizer | 4 | $59 |
| Biogen | 4 | $59 |
| Merz North America, Inc. | 1 | $42 |
| Avanir Pharmaceuticals, Inc. | 2 | $38 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| Grifols USA, LLC | 2 | $36 |
| Greenwich Biosciences, Inc. | 2 | $28 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Merz Pharmaceuticals, LLC | 1 | $19 |
| Almatica Pharma LLC | 1 | $18 |
| Catalyst Pharmaceuticals, Inc. | 1 | $18 |
| AstraZeneca | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Assertio Therapeutics, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| GE HealthCare | 1 | $15 |
| Tanabe Pharma America, Inc. | 1 | $13 |
| Lilly USA, LLC | 1 | $12 |
| Neurocrine Biosciences, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$5,927
- APTIOM$4,910
- RNS Neurostimulator Kit$151
- VNS Therapy$125
How this compares
$17,972 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Dallas
- Nirav PavasiaDallas$1.4M
- Benjamin GreenbergDallas$773K
- Waleed El-FekyDallas$587K
- Adnan SubeiDallas$477K
- Steven HerzogDallas$461K
- Priyanka ChaudhryDallas$329K
- Deborah FriedmanDallas$284K
- Mark AlbertsDallas$212K
- Aanchal TanejaDallas$169K
- Salman BhaiDallas$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.